A-935142
目录号 : GC70380A-935142是一种人类以太-a-go-go相关基因(hERG,Kv 11.1)通道激活剂。
Cas No.:1031335-85-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
A-935142 shortens the action potential duration (APD90) in guinea pig atrial tissue and canine cardiac Purkinje fibers[1].
A-935142 shortens cardiac action potentials and enhances the amplitude of the hERG current in a concentration- and voltage-dependent manner. A-935142 (60μM) increases both outward and inward K(+) current as well as the slope conductance of the linear portion of the fully activated I-V relation. A-935142 significantly reduces the time constants τ of hERG channel activation at two example voltages (-10 mV: tau=100+/-17 ms vs. 164+/-24 ms, n=6, P<0.01; +30 mV: tau=16.7+/-1.8 ms vs. 18.9+/-1.8 ms, n=5, P<0.05) and shifts the voltage-dependence for hERG activation in the hyperpolarizing direction by 9 mV[2].
References:
[1]. Ohno H, et al. Absorption, disposition, metabolism and excretion of [14C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica. 2019 Apr;49(4):463-473.
[2]. Liu X, et al.Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. Life Sci. 2012 Apr 20;90(15-16):607-11.
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8381 mL | 14.1904 mL | 28.3809 mL |
5 mM | 0.5676 mL | 2.8381 mL | 5.6762 mL |
10 mM | 0.2838 mL | 1.419 mL | 2.8381 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。